FORGE in the News
January 9-11, 2017: FORGE Life Science President & CEO, Lillian Chiang, will present at 9th Annual Biotech Showcase 2017 investor conference in San Francisco, CA. Read more
October 27, 2016: FORGE Life Science Board Chairman, Thomas Shenk, presented at China Renaissance’s 4th Healthcare and Life Sciences Leadership Summit in Shanghai, China.
October 20, 2016: BioCentury Innovations covers FORGE Life Science. “Sirtuins forge ahead – How FORGE Life Science is targeting sirtuins to treat viral infections.” Read more
September 20, 2016: FORGE Life Science named one of 2016’s Best University Startups by the National Council of Entrepreneurial Tech Transfer (NCET2). Read more
August 5, 2016: FORGE Life Science is awarded its fourth grant from the NIH National Institute for Allergy and Infectious Disease titled, ”Sirtuin Agonists as Pan-Influenza Antivirals" (1R44AI122488-01). Read more
June 27, 2016: Mid Atlantic Bio Angels chooses FORGE Life Science for its first Closed-End Investing Pool investment. Read more
June 1, 2016: FORGE Life Science secures an in-kind services investment from ShangPharma Investment Group Limited providing FORGE medicinal chemistry and DMPK contract research services from the service division of the ShangPharma group, ChemPartner, a leading contract research organization.
October 19, 2015: FORGE Life Science Board Chairman, Thomas Shenk is keynote speaker at the BioCentury China Healthcare Summit in Shanghai, China. His talk, “Been There, Done That, Doing It Again” tells his personal story as a serial entrepreneur from ImClone Systems to FORGE Life Science.
August 1, 2015: Dr. Eain Murphy, formerly Associate Professor of Virology at the Cleveland Clinic Lerner Research Institute, joins FORGE Life Science as Head of Biology.
February 5, 2015: FORGE Life Science is awarded it's third grant from the NIH National Institute for Allergy and Infectious Disease titled, "An Antiviral to Treat Progressive Multifocal Leukoencephalopathy (PML)" (1R43AI118232-01). Read more
December 16, 2014: FORGE Life Science Founders, Ileana Cristea, Emre Koyuncu, and Thomas Shenk publish their breakthrough discovery that “Sirtuins Are Evolutionarily Conserved Viral Restriction Factors”. Read more
October 14, 2014: FORGE Life Science receives JumpStart Award announced at PA BIO Life Sciences Futures annual meeting in Philadelphia, PA. Read more
September 2014: FORGE Life Science featured in the Innovator's Corner of PharmaVoice magazine. Read more
August 1, 2014: Dr. Stacy Remiszewski, former Director of Chemistry, Section Head for Oncology Chemistry at Hoffmann-La Roche, joins FORGE Life Science as Head Of Chemistry.
June 4, 2014: FORGE Life Science LLC is awarded a second grant from the NIH National Institute for Allergy and Infectious Disease titled, "A Single Antiviral to Treat Multiple Opportunistic Infections" (1R43AI114079-01). Read more
February 5, 2014: FORGE Life Science LLC grant titled, "Host-Targeted Mechanism of Action for Treatment of Seasonal and Pandemic Influenza", is awarded by the NIH National Institute for Allergy and Infectious Diseases (1R43AI110048-01). Read more
January 28, 2014: FORGE Life Science LLC exclusively licenses Sirtuin-Antiviral Technology from Princeton University.
January 14, 2013: FORGE Life Science LLC leases BSL2+ facilities from the Pennsylvania Biotechnology Center.